MOTIVATE-C: a randomised trial to evaluate the impact of financial incentives on the rate of initiation of antiviral therapy in people with hepatitis C - Trial ANZCTR12623000024640
Access comprehensive clinical trial information for ANZCTR12623000024640 through Pure Global AI's free database. This Not Applicable trial is sponsored by The University of Sydney and is currently Recruiting. The study focuses on Hepatitis C.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Australian New Zealand Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The University of Sydney
National Health and Medical Research Council, 2020 Medical Research Future Fund (MRFF) - PPHR Initiative - Efficient use of existing medicines
Timeline & Enrollment
Not Applicable
May 15, 2023
N/A
Primary Outcome
Initiation of Direct-acting antiviral (DAA) therapy for hepatitis C infection, as evidenced by documented receipt of a valid dispensed DAA medication.
Summary
Financial incentives (for patients and primary care providers) may be a straightforward strategy for improving the uptake of hepatitis C treatment in primary care. In the MOTIVATE-C project, individuals with hepatitis C will be randomly assigned to usual care (no incentive) or to receive incentives of various dollar values (AUD 0 to AUD 1000), provided in conjunction with/without a co-incentive payment to the participant’s nominated primary care provider, for commencing hepatitis C treatment within the context of a supported treatment framework. By assigning patients to different values of incentive and evaluating their effect on treatment initiation, we aim to directly inform the future implementation of incentives by identifying the most cost-efficient strategy.
ICD-10 Classifications
Data Source
Australian New Zealand Clinical Trials Registry
ANZCTR12623000024640
Non-Device Trial